Heart failure as a consequence of myocardial fibrosis is the world’s biggest killer and represents a significant unmet medical need. No therapies currently exist that either directly target the heart or the fibrotic process itself. We have discovered a heart-specific regulator of fibrosis – the long noncoding RNA, Wisper. By using our first-in-class proprietary approach to target Wisper, we are able to block myocardial fibrosis and treat heart failure in pre-clinical animal models.

We are developing a first-in-class biopharmaceutical therapy to treat heart failure.

In response to the rising demand for healthier foods, we are developing functional and structural mimics of Human Milk Oligosaccharides (HMOs) for the consumer health market. Our products reproduce the natural diversity and complexity of HMOs and have been shown to be beneficial in preventing the onset of gut infection and protect against the effect of antibiotic use.

Why is the GNUbiotics ingredient unique?

• The most diverse HMO mimic product available. The more diverse, the more proven efficiency.
• Ingredient produced with no GMO or enzymatic processes. A 100% natural source.
• Proven efficacy for microbiome modulation.

Leveraging its’ key technological competences, polymers chemistry, cell biology and materials sciences, Volumina Medical has developed a technology platform applicable to different areas of reconstructive, plastic and aesthetic surgery, a fast-growing market (+11% annual growth since 2013, expected to reach 12% over the next five years).

The company is committed to becoming a leading and reliable actor in the field of regenerative technologies of soft tissues, providing safe, cutting-edge technologies, limiting uncertainty and saving time for both patients and surgeons. The company strives to grow through its strategy: Understand, Execute, Optimize, Accelerate.

Volumina Medical’s mission is to develop its first product, an injectable scaffold, and to obtain the approval to penetrate the European market first with an indication for intermediate volumes.

We are SEED Biosciences, a spin-off from the Swiss Federal Institute of Technology (EPFL). We make DispenCell. One click, one cell.

AC BioScience is a start-up biotech company dedicated to developing new therapies to fight a range of cancers. Founded by Andreas Schläpfer and Professor Christian Auclair, the company is leading a paradigm shift in cancer therapeutics. Our primary focus is on developing personalized therapies for tumoral pathologies. We have obtained patent protection for one ground-breaking cancer therapy and have filed patents for two others.

Cellestia is giving hope to cancer patients who have no other treatment or therapy options by developing innovative targeted therapies. Our drug discovery platform is built on a unique mode of action of targeting protein-protein interactions (PPI) with small molecules. Together with companion diagnostics, Cellestia provides a first-in-class solution for NOTCH-driven cancers. Cellestia is a privately owned clinical-stage biopharma company (phase I) led by an experienced team of scientists, drug developers and business professionals.

Genknowme SA is an innovative life sciences company dedicated to transforming breakthrough research and clinical science into actionable lifestyle epigenetics tests. We are developing a simple at-home blood test that identifies key biogenetic markers to help adults track, maintain and improve their well-being and potential longevity. Our product brings us beyond DNA, analyzing the epigenome. We aim to provide keys and tools for adults who want to objectively monitor the effects of their efforts on their well-being.

Iridescent Biosciences developed a multiplex signal amplification nanotechnology for the detection of key biomolecules. Our technology, Multimodal Universal Signal Enhancement (MUSE), facilitates the multiplex detection of transcripts and proteins. MUSE is sensitive and fast and can be easily incorporated into current In Situ Hybridization and Immunofluorescence workflows.

ND BioSciences is a biotechnology company that was founded with the mission of developing and providing innovative technologies, solutions, tools, assays and services to accelerate the development of early diagnostics and therapies for neurodegenerative diseases. ND BioSciences has developed powerful proprietary technologies and innovative tools that enable for the first time the reproduction, at both the biochemical and structural levels, of the proteoforms and pathological species found in the brain and biological fluids of patients suffering from neurodegenerative diseases.

Bioinnovation Solutions SA brings expertise in generating high resolution bacterial and viral transmission and digital phylogenetic data produced using proprietary AI and genomic technologies. This technology generates highly reproducible quantitative data that is superior to other detection systems (such as qPCR) and enables faster, simpler, and more sensitive next generation sequencing for researchers and clinical trials compared to standard methodologies. Having a very accurate and targeted approach, the Bioinnova DxSeqTM system also reduces bioinformatic burden and associated costs.